{
  "ticker": "EMD",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959563",
  "id": "02959563",
  "pages": 5,
  "price_sensitive": true,
  "date": "20250618",
  "time": "0944",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250618/pdf/06kvqz9l30j156.pdf",
  "summary": "### **Material Information Summary**  \n\n#### **Key Highlights:**  \n1. **Medibank Partnership**  \n   - Medibank (ASX: MPL) will fund eligible customers' participation in Emyria\u2019s PTSD care program (Empax Model) at Perth Clinic, with **no out-of-pocket costs** (subject to policy terms).  \n   - **Multi-year agreement**\u2014first major private insurer-backed PTSD psychotherapy program in Australia.  \n   - Treatment costs **$20,000\u2013$30,000 per patient**; no patient quotas.  \n\n2. **Capital Raising (Placement)**  \n   - **$4M raised** (before costs) via placement at **$0.024/share** (4% discount to last close, 6.15% discount to 15-day VWAP).  \n   - **Timetable**:  \n     - **First tranche**: ~120.2M shares (settlement ~25 June 2025).  \n     - **Second tranche**: ~46.5M shares (subject to shareholder approval at EGM, August 2025).  \n   - **Use of proceeds**: Fund PTSD program rollout and working capital.  \n\n3. **Loyalty Options**  \n   - Post-placement, shareholders to receive **1 free option per 4 shares held** (exercise $0.05, expiry 18 months).  \n\n4. **Strategic Expansion**  \n   - Plans to scale Empax Model nationally, targeting Eastern states and additional insurers.  \n\n---  \n**Omitted**: Operational details, director participation, broker fees, and forward-looking disclaimers (non-material for trading decisions).",
  "usage": {
    "prompt_tokens": 3365,
    "completion_tokens": 342,
    "total_tokens": 3707,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-17T23:53:02.362400"
}